Mon Sep 30 02:38:30 UTC 2024: ## Check-Cap Short Interest Drops Amidst “Sell” Rating from StockNews.com
**Tel Aviv, Israel** – Check-Cap Ltd. (NASDAQ: CHEK), a clinical stage medical diagnostics company focused on colon cancer screening, saw a significant decrease in short interest during September. As of September 15th, short interest totaled 56,000 shares, representing a 14.6% drop from the August 31st figure of 65,600 shares.
This decline in short interest comes amidst a “sell” rating issued by StockNews.com on September 22nd. The research firm cited [reasons for the “sell” rating, if provided in the original text] as the basis for their recommendation.
Despite the short interest drop, Check-Cap’s stock traded down $0.18 on Friday, hitting $1.17. The company’s market capitalization sits at $6.87 million, with a P/E ratio of -0.39 and a beta of 0.39.
Check-Cap’s C-Scan system, a capsule-based colon screening technology, utilizes ultra-low-dose X-rays to detect precancerous polyps and other abnormalities. The system consists of the C-Scan Cap, C-Scan Track, and C-Scan View software.
Investors are closely watching Check-Cap’s progress as the company continues to develop its innovative screening technology.
First Piper 